CD 93 Marks a Non-Quiesc ent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia Graphical
暂无分享,去创建一个
[1] Stefan Fröhling,et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. , 2013, Blood.
[2] Angelo J. Canty,et al. Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.
[3] Ash A. Alizadeh,et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker , 2011, Proceedings of the National Academy of Sciences.
[4] M. Konopleva,et al. Leukemia stem cells and microenvironment: biology and therapeutic targeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Ash A. Alizadeh,et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. , 2010, JAMA.
[6] M. Sramko,et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. , 2010, Blood.
[7] O. Ohara,et al. Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells , 2010, Science Translational Medicine.
[8] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[9] I. Weissman,et al. CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.
[10] Howard Y. Chang,et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.
[11] Satoshi Tanaka,et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.
[12] M. Cleary,et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.
[13] I. Weissman,et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.
[14] M. Cleary,et al. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.
[15] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[16] M. Noble,et al. Cancer stem cells. , 2006, The New England journal of medicine.
[17] P. Guldberg,et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.
[18] Irving L. Weissman,et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates , 2005, The Journal of experimental medicine.
[19] G. V. van Dongen,et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.
[20] G. Sauvageau,et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. , 2005, Blood.
[21] P. Sharp,et al. Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Taylor,et al. Murine CD93 (C1qRp) Contributes to the Removal of Apoptotic Cells In Vivo but Is Not Required for C1q-Mediated Enhancement of Phagocytosis1 , 2004, The Journal of Immunology.
[23] M. Malumbres,et al. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15Ink4b-deficient mice , 2003, Oncogene.
[24] M. Cleary,et al. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.
[25] L. Larocca,et al. Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis , 2003, Leukemia.
[26] Douglas R Lowy,et al. p16INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB , 2003, Oncogene.
[27] M. Simon,et al. C1qRp defines a new human stem cell population with hematopoietic and hepatic potential , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] P. Gasque,et al. Human C1qRp Is Identical with CD93 and the mNI-11 Antigen But Does Not Bind C1q1 , 2002, The Journal of Immunology.
[29] A. Ganser,et al. Tumor suppressor genes in normal and malignant hematopoiesis , 2002, Oncogene.
[30] J. Nolta,et al. Molecular mechanism of transforming growth factor b – mediated cell-cycle modulation in primary human CD 34 1 progenitors , 2001 .
[31] E. Nelson,et al. C1qRp, a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue , 2001, Journal of leukocyte biology.
[32] R. Liang,et al. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] C. Li,et al. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[35] L. Larocca,et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. , 2000, Experimental hematology.
[36] I. Lemischka,et al. The molecular characterization of the fetal stem cell marker AA4. , 1999, Immunity.
[37] H. Drexler. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.
[38] A. Tenner,et al. C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. , 1998, Journal of immunology.
[39] M. Cleary,et al. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX–ENL , 1997, The EMBO journal.
[40] J. Dick,et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.
[41] J. Dick,et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[42] A. Henschen-Edman,et al. cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. , 1997, Immunity.
[43] J. Herman,et al. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.
[44] M. Caligiuri,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.
[45] 菊繁 吉謙. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells , 2012 .
[46] K. Ohyashiki,et al. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. , 2005, Leukemia research.
[47] I. Wong,et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.